1. Market Research
  2. > Pharmaceutical Market Trends
Global Biologics Drug Discovery Market Analysis and Forecast, (2017-2025) (Focus on Method/Phase, Product Type, Manufacturer Type and Competitive Landscape)

Global Biologics Drug Discovery Market Analysis and Forecast, (2017-2025) (Focus on Method/Phase, Product Type, Manufacturer Type and Competitive Landscape)

  • July 2017
  • 358 pages
  • ID: 5045735

Summary

Table of Contents


Description
The pharmaceutical Industry is a multibillion market consisting of innovator drugs & generics. The pharmaceutical market consists of a companies involved in the research, development, manufacturing and commercialization of drugs for human & animal use.

Geographically, biologics have registered near double digit annual growth rate, whereas, the pharmaceutical drugs registered only single digit annual growth rate, in the past five years.

This double digit growth was largely fuelled by the substantial investments of the major pharmaceutical companies, who realized the potential of the market quite early. Biologics are defined as pharmaceutical products obtained from living cells or micro-organisms. These are complex & large molecules consisting of proteins, peptides, nucleic acids, sugars, cellular structures or a combination of these.

The biologics drug discovery involves target identification, hit-to-lead stage, lead identification & optimization. Technologies used for the development of biologics include genomics, proteomics, microarrays, cell cultures, phage display technologies and monoclonal antibody technologies among others. The market analysis includes an in-depth examination of the key ecosystem players and key strategies & developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities and challenges) and industry analysis.

The purpose of the study is to gain a holistic view of the biologics drug discovery market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the biologics drug discovery market. The market has been segmented into ‘product’, ‘method’, ‘manufacture’ and ‘geographical regions’.

The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global biologics drug discovery market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that is going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global biologics drug discovery market and assesses the factors governing the same.

The answers to the following key questions can be derived from this report:
• What are the major market drivers, challenges and opportunities in the global biologics drug discovery market and their case studies?
• How the biologics drug discovery market evolve and what did is its scope in the future?
• What is the market share of the leading segments and sub-segments of the global biologics drug discovery market in 2016 and 2025?
• How will each segment of the global biologics drug discovery market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2025?
• What are the influencing factors that may affect the market share of the key players?
• How will the industry evolve during the forecast period between 2016 and 2025?
• What are the key developmental strategies implemented by the key players to stand out in this market?
• What will be the growth rate of the outsourced manufacturing segment during the forecast period?
• Who are the key outsourced manufacturers of the biologics drug discovery market market?
• How the market has been segmented on the basis of phase/method? Which method is highly adopted in the biologics drug discovery process?
• Which technologies have been covered in the Target Identification phase?
• What will be the value of oncology biologics drug discovery segment by 2025?
• Which geographical location will contribute to the highest sales of biologics?
• In Europe, which country is dominating the biologics drug discovery market? Also, which country will show the highest growth rate?

The key players which have significant contributions to the biologics drug discovery market are Albany Molecular Research Inc., GenScript, F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Sanofi, Merck & Co., Inc., Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, AbbVie Inc., Amgen Inc., Lilly, Bristol-Myers Squibb, Novo Nordisk, Merck KGaA, Allergan, Plc, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., and Bayer AG, and Biocon Ltd. among others.

Executive Summary
The introduction of biologic therapies gave a new ray of hope for people suffering from chronic inflammatory diseases. Biologics effected their life not only by reducing dependency on health and welfare systems but also by improving their physical function to live independently. The entry of biosimilars makes these effective therapies more affordable, though the concern of after effects still exists.

The purpose of the study is to gain a holistic view of the biologics drug discovery market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the biologics drug discovery market. The market has been segmented into ‘product’, ‘method’, ‘manufacture’ and ‘geographical regions’.

The global biologics drug discovery market was estimated to be $8.9 billion in 2016 and is estimated to grow over $22.7 billion by 2025. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine is expected to fuel the demand for biologics drugs in the future.

Moreover, ever-increasing understanding of the cell physiology and stress, as well as the factors involved in protein production and heterologous gene expression have empowered the use of different living factories in the development of novel therapeutic biologic drugs.

The global biologics drug discovery market can be segmented based on the basis of phase of discovery into target identification, hit generation, lead identification & lead optimization.

The major contributor towards the market in 2016 was the lead optimization phase. Based on the manufacture type, the market is segmented into in-house & outsourced. The in-house market for the global biologics drug discovery was estimated to be $6.5 billion in 2016. The CAGR was highest for the out-sourced manufacturing.

Moreover, based on the product type, monoclonal antibody is anticipated to be the major contributor to the market. The market for the drug discovery of monoclonal antibody is expected to reach $10.7 billion by 2025. The next contributing segment is recombinant proteins.

Geographically, the largest contributor to the growth of the global biologics drug discovery market was found to be North America due to the presence of pharmaceutical companies involved in R&D of biologics. This was followed by Europe. The fastest growing region was Asia-pacific due to the increasing presence of Contract Research Organisations (CRO).

Biologics are expected to contribute 50% to the sales of the top 100 products during the forecast period. This will lead to increased investment in the global biologics drug discovery market in future. For instance, in 2016, among the most valued R&D projects were Roche’ Ocrelizumab & Sanofi’s Dupilumab. And in 2017, Ocrevus (Ocrelizumab) & Dupixient (dupilumab) were among the top 2 product launches so far.

The biologics market presents with opportunities to change the treatment options. The development of antibody drug conjugates, glycosylated antibodies, Chimeric Antigen Receptor-T (CAR-T) cell therapy and bio-betters presents opportunities for the further growth of the biologics drug discovery market.

The report provides in-depth SWOT analysis of different key players of the market, supported by extensive financial summary of each. Some of the key players are F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Sanofi, Merck & Co., Inc., Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, Gilead Sciences, Inc., AbbVie Inc., Amgen Inc., Eli Lilly and Company, Bristol-Myers Squibb GmbH, Novo Nordisk, Merck KGaA and Allergan, Plc.

Countries Covered
North America
Europe
Asia-Pacific
RoW

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
2018 Global Clinical Chemistry and Immunodiagnostics Market: US, Europe, Japan--Analyzers and Reagents-- Supplier Shares and Sales Segment Forecasts by Test and Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities

2018 Global Clinical Chemistry and Immunodiagnostics Market: US, Europe, Japan--Analyzers and Reagents-- Supplier Shares and Sales Segment Forecasts by Test and Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities

  • $ 23500
  • Industry report
  • June 2018
  • by Venture Planning Group

The report is a seven-country strategic analysis of major business opportunities emerging in the clinical chemistry and immunodiagnostic markets during the next five years. The report explores future ...

2018 POC Diagnostic Testing Market: Reagent and Instrument Supplier Shares, Sales Segment Forecasts for 300 Tests, Emerging Technologies, Instrumentation Review, Competitive Landscape, Opportunities for Suppliers

2018 POC Diagnostic Testing Market: Reagent and Instrument Supplier Shares, Sales Segment Forecasts for 300 Tests, Emerging Technologies, Instrumentation Review, Competitive Landscape, Opportunities for Suppliers

  • $ 16600
  • Industry report
  • August 2018
  • by Venture Planning Group

This new report provides comprehensive analysis of the ten POC market segments, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging ...

Immunodiagnostics: Spot Fast-Growing Market Segments--Therapeutic Drug Monitoring, Endocrine Function, Tumor Markers, Special Chemistry, Immunoproteins, Drugs of Abuse

Immunodiagnostics: Spot Fast-Growing Market Segments--Therapeutic Drug Monitoring, Endocrine Function, Tumor Markers, Special Chemistry, Immunoproteins, Drugs of Abuse

  • $ 15900
  • Industry report
  • June 2018
  • by Venture Planning Group

This comprehensive seven-country report contains 1,115 pages and 450 tables. The report explores future trends in the U.S., five major European countries (France, Germany, Italy, Spain, UK) and Japan; ...


ref:plp2017

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on